PeppiLibrary

Metabolic

Survodutide peptide reference

GLP-1/glucagon dual agonist. Phase 3 in obesity and MASH.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Survodutide notes
Default dose label600 mcg
Preferred routeSubQ
Frequency label1× weekly
Storage window28 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Phase 2 data positive; Phase 3 ongoing — not yet approved

Investigational

Route map

How records are usually labeled

1 SubQ

Rotate weekly between sites.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; do not freeze.
After mixRefrigerate 2–8 °C, use within 28 days.
Use-by cue28 days after mixing
Mixed vial window28 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 600 mcg
Route SubQ
Review 28d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Survodutide. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Survodutide is a synthetic dual agonist of GLP-1 and glucagon receptors, co-developed by Boehringer Ingelheim and Zealand Pharma. The dual mechanism couples appetite suppression and gastric slowing (GLP-1) with increased energy expenditure and lipolysis (glucagon). Phase 2 trials in obesity reported up to 19% weight reduction at 46 weeks; Phase 3 SYNCHRONIZE program is ongoing. Also under investigation for MASH (NAFLD).

Also known as: BI-456906.

Obesity research (Phase 3 SYNCHRONIZE)MASH / NAFLD researchT2D research

Mechanism and timing snapshot

Dual agonist of GLP-1 and glucagon receptors. Combines GLP-1 effects (glucose-dependent insulin, gastric slowing, appetite suppression) with glucagon effects (increased energy expenditure, hepatic lipolysis).

Onset labelNot listed
Catalog onset field, when available.
Half-life label144 hr
~6 days; weekly dosing
Duration label168 hr
Catalog duration field, when available.
subQ High
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose600 mcg
Catalog dose range600 mcg - 6 mg
Default routeSubQ
Frequency label1× weekly
Best time labelSame day each week, any time of day.
Food noteNone for the injectable form.

Catalog protocol note

Trial titration: 0.6 mg weekly × 2 weeks → escalate every 2–4 weeks up to 6 mg max.

Routes and site notes

Available route labelsSubQ
Preferred route labelSubQ
Common site labelsAbdomen, Thigh, Upper arm
Site rotation noteRotate weekly between sites.

Chemistry

SequenceModified GLP-1/glucagon hybrid backbone with C18 fatty acid; ~30 amino acids
Amino acids30
Molecular formulaNot listed
Molecular weight4500 Da

Vial, reconstitution, and storage

Supply formLyophilized powder (compounded only — no commercial form yet)
Typical vial size5 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration noteCompounded 5 mg in 2 mL → 0.24 mL = 0.6 mg starting dose.
Before reconstitutionRefrigerate 2–8 °C; do not freeze.
After reconstitutionRefrigerate 2–8 °C, use within 28 days.
Reconstituted shelf life28 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Nausea (~30%)
  • Diarrhea or constipation
  • Decreased appetite
  • Fatigue
  • Pancreatitis
  • Increased heart rate (glucagon component)
  • Gallbladder issues

Contraindications and warnings

  • Personal/family history of medullary thyroid carcinoma
  • MEN 2 syndrome
  • Pregnancy
  • Pancreatitis history
  • Investigational — not yet FDA-approved.
  • Glucagon component may raise heart rate and acutely raise blood glucose; monitor.

Other considerations

  • Glucagon receptor activation is what differentiates this from semaglutide — adds energy-expenditure mechanism.
  • Phase 2 weight-loss data is strong but not yet exceeding tirzepatide head-to-head.
  • Available only via compounding pharmacies until approval.

Evidence and regulatory context

Evidence levelPhase 2 data positive; Phase 3 ongoing — not yet approved
FDA approvedNo
Regulatory statusInvestigational
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteOther GLP-1 or glucagon agonists
Typical cycle labelongoing
Typical break labelNot typically cycled
Cycle guidanceUsed continuously per trial protocols.

Tracking tips

  • Investigational — Phase 3 still running.
  • Glucagon component means heart rate may run a few BPM higher than baseline; monitor.
  • Compounded supply quality varies; vet your source carefully.

References

Track it in Peppi

Keep Survodutide records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Survodutide?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Survodutide?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Survodutide records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026